Tagged with OP

Opinion Carla Smith is a healthcare thought leader with nearly 30 years’ experience. She champions transformational strategy, governance, and policy in the health sector, particularly in the areas of digital health and health IT. In this article, Ms Smith discusses the massive potential of digital therapeutics in helping patients manage their…

Opinion After her son was diagnosed with SYNGAP1 – an extremely rare gene mutation – Monica founded Bridge the Gap – SYNGAP Education and Research Foundation to support families of those suffering from the illness and to accelerate the path to better therapies. Here Monica discusses the incredibly low rate of treatment options for…

Generics Over the last ten years, generic medicines have increased access to medicines by over 100% in 7 key therapeutic areas and have provided massive savings for healthcare systems in Europe. In this exclusive interview with Adrian van den Hoven, director general of Medicines for Europe, we discuss the importance of…

Opinion Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In this article, he gives his predictions for the political landscape in healthcare for 2019.  The challenges for firms are painfully apparent—there is bipartisan support in the US to lower drug prices, a pervasive sense that traditional advocacy methods are failing in today’s political climate,…

Europe The Top Pharma Markets in Europe for 2016 according to the latest EFPIA figures. Germany leads the way, with a market size of EUR 30.815 billion, followed by France and Italy.

USA Chester “Chip” Davis, Jr, the President and CEO of the Association for Accessible Medicines (AAM) weighs in on the issue of drug shortages in America.    An uncertain environment for generic manufacturers imperils the sustainability of patient access to low-cost generic medicines.   The unavailability of prescription medicines can cause physical suffering,…

Europe 125 medicines for rare diseases were approved by the EMA between 2004 and 2014, of which 71 were granted orphan drug status. This chart shows the availability of 112 of these drugs across European countries. The largest number of medicines for rare diseases were in continuous use in Germany and…

Opinion Axel Schumacher, co-founder and chief scientific officer of Shivom, a data-driven next generation precision-medicine company in the blockchain space, calls for Pharma to leverage big-data on a global level to ensure all patients have a therapy option.    The key to success for pharma players is to sponsor the accumulation of…

Mexico David Peña Castillo, president and founder of the Mexican Federation of Rare Diseases (FEMEXER), addresses the problem of patients deserting therapies.   In Mexico, approximately 15 percent of patients treated with therapies for rare diseases, dismiss the concept of adherence to treatments. In Latin American Countries such as Mexico, keeping…

Top 10 In 2018 we started approaching thought leaders across the life sciences sector to contribute their opinions and insights and provide valuable insider knowledge to our readers. Over the past year, we have received some fascinating and enlightening outlooks from our peers with topics spanning from blockchain and AI to pharma’s…

Mexico Cristobal Thompson is the executive director at AMIIF (Asociacion Mexicana de Industrias de Investigacion Farmaceutica). The AMIIF represents more than 60 global companies with the aim of contributing to improving health in Mexico through innovative medicine. Here Thompson discusses the need for stronger public-private sector alliances in the push towards universal…

Top 10 2018 has been an exciting year in world health and our team has spanned the globe to bring you in-depth country reports and high profile interviews with leaders from the life science industry. Bringing you a diverse array of insights – from those spearheading the medical cannabis revolution to the…